UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN
DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
SOMERVILLE, N.J., Nov. 19 /PRNewswire/ -- Unimed, Inc. (NASDAQ: UMED) announced today that its has signed a collaboration agreement with Debiopharm S.A. of Switzerland to support European development of Marinol (dronabinol) to enhance appetite and reduce weight loss in AIDS patients.
Under the terms of the agreement, Debiopharm will manage and fund all studies required to develop a regulatory dossier and gain marketing approval of Marinol in European markets. As development progresses, Unimed and Debiopharm will jointly identify marketing partners in Europe, outside of Spain and Portugal where Unimed has an agreement with
Lacer S.A. The companies will share licensing fees and royalties from these marketing partners under an agreed upon formula. Unimed will retain rights to supply product to these marketing partners.
The clinical trials will be conducted in a number of renowned European AIDS clinics, under the leadership of Pasteur Institute, Paris, where Professor Luc Montagnier and others have made great contributions to AIDS research and treatment.
"There is a significant opportunity for Marinol in Europe where the number of AIDS patients is increasing rapidly," said Dr. R.-Y. Mauvernay, director of Debiopharm's Biological and Pharmaceutical Development Group. "The involvement of Pasteur Institute will give the project the expertise and credibility required to progress rapidly."
"Debiopharm has a professional development organization which has been successful in brining several pharmaceuticals to market," said Harold J. Tenoso, Ph.D., Unimed's chairman and chief executive officer. "Through this collaboration, we can substantially enhance the value of the product before entering discussions with marketing partners."
Debiopharm develops promising new chemical and biological entities which have reached an advanced stage of development. It has already brought several products to market in the cancer field. Debiopharm is a member of The Debio Group, a Swiss financing company specializing in the development of drugs and delivery systems.
Marinol is Unimed's antinausea pharmaceutical for the treatment of cancer chemotherapy patients. It is currently undergoing clinical trials for appetite stimulation and prevention of weight loss in AIDS patients. The FDA has granted Marinol Orphan Drug designation for this use.
Unimed, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients. The company has brought two pharmaceuticals to market and has a portfolio of drugs in development.
/CONTACT: Charles P. Harrison, president of Unimed, 908-526-6894/
(UMED) CO: Unimed Inc. ST: New Jersey IN: MTC SU: SH-TS -- NY011 -- 4798 11/19/91 09:06 EST